European Companies Search Engine
EU funding (€2,808,163): Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic Hor16 Mar 2020 EU Research and Innovation programme "Horizon"
Overview
Text
Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
I-MOVE-COVID-19 aims to obtain epidemiological, clinical and virological information about COVID-19 and patients infected with SARS-CoV-2, through provision of a flexible surveillance platform (adaptable to the epidemiological situation), research studies, hypothesis-testing and evaluation of public health interventions (e.g. vaccination, antivirals) in order to contribute to the knowledge base, guide patient management, and inform the public health response. This will be achieved through adaptation and expansion of the existing, long-running, Europe-wide influenza surveillance network (I-MOVE) to include COVID-19. The network includes primary care networks, hospitals, national laboratory reference centres in eleven countries. I-MOVE-COVID-19 priority activities and research projects will be selected based on ECDC/WHO input and the proposal’s detailed list. These will be conducted by mobilising an existing large European multidisciplinary network, combining the expertise and resources of groups working in surveillance (epidemiological, clinical, virological), respiratory disease research, and evaluation of vaccines/treatments. Through protocol sharing and pooling European results, questions will be answered which could not be efficiently answered by countries acting alone. I-MOVE-COVID-19 will share study results rapidly and widely with national and international partners and with the wider scientific community and contribute to clinical management of patients and public health preparedness and response to COVID-19.
Funded Companies:
| Company name | Funding amount |
| Agence Nationale de Sante Publique | €0.00 |
| Assistance Publique Hopitaux de Paris | €99,700 |
| Centre Hospitalier Universitaire Montpellier | €28,200 |
| €28,200 | |
| €137,850 | |
| Epiconcept | €509,063 |
| Epiconcept UK Ltd. | €0.00 |
| €90,350 | |
| €0.00 | |
| €0.00 | |
| €0.00 | |
| €109,350 | |
| Hospices Civils de Lyon | €28,200 |
| INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE | €187,150 |
| Institut National de la Sante et de la Recherche Medicale | €2,500.00 |
| Institut Pasteur | €79,000 |
| €123,900 | |
| €0.00 | |
| €265,250 | |
| €123,900 | |
| €110,900 | |
| €40,000 | |
| €0.00 | |
| €174,250 | |
| €201,250 | |
| €45,000 | |
| Sorbonne Universite | €60,350 |
| €140,350 | |
| The Chancellor, Masters and Scholars of the University of Oxford | €59,000 |
| Universite de Corse Pascal Paoli | €10,000.00 |
| University of Strathclyde | €0.00 |
| VACCINE SAFETY INITIATIVE VIVI e. V. | €92,450 |
| Vrije Universiteit Brussel | €62,000 |
Source: https://cordis.europa.eu/project/id/101003673
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Agence Nationale de Sante Publique - EU funding (€2,808,163): Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
